Latest news

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related

ROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case

ROCKVILLE, Md., July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be

Robert Avery, MD, California Retina Consultants

David S. Boyer, MD, Retina-Vitreous Associates Medical Group

Carolina Tesi-Rocha, M.D., Clinical Professor of Neuromuscular Medicine, Stanford Medicine Children’s Health